Radiomic signatures associated with longitudinal TNM downstaging for prognostic stratification in breast cancer.
2/5 보강
OpenAlex 토픽 ·
Radiomics and Machine Learning in Medical Imaging
Breast Cancer Treatment Studies
MRI in cancer diagnosis
[OBJECTIVES] The tumor-node-metastasis (TNM) staging system is vital for evaluating treatment efficacy in breast cancer patients undergoing neoadjuvant chemotherapy (NACT).
- 표본수 (n) 292
- p-value p < 0.001
- p-value p = 0.004
APA
Ming Fan, Weihao Liu, et al. (2026). Radiomic signatures associated with longitudinal TNM downstaging for prognostic stratification in breast cancer.. Insights into imaging, 17(1). https://doi.org/10.1186/s13244-026-02284-7
MLA
Ming Fan, et al.. "Radiomic signatures associated with longitudinal TNM downstaging for prognostic stratification in breast cancer.." Insights into imaging, vol. 17, no. 1, 2026.
PMID
41999532
Abstract
[OBJECTIVES] The tumor-node-metastasis (TNM) staging system is vital for evaluating treatment efficacy in breast cancer patients undergoing neoadjuvant chemotherapy (NACT). However, the prognostic significance of longitudinal TNM changes remains unclear. This study aimed to develop radiomic signatures associated with TNM downstaging (dTNM) and to evaluate their utility in prognostic stratification for breast cancer patients.
[MATERIALS AND METHODS] The prognostic analysis included a development cohort (n = 292) and two external validation sets (n = 180, n = 61), all with DCE-MRI data and follow-up information. A random forest-based multitask model was developed using radiomic features from DCE-MRI to predict recurrence, pathological complete response (pCR), and dTNM in the development cohort, stratifying patients into distinct groups. The model's discriminative performance was assessed with the area under the curve (AUC). In the external validation set, a multivariable Cox proportional hazards model evaluated the prognostic significance of the groups stratified by the radiomic signatures.
[RESULTS] The multitask model, incorporating 17 imaging features, achieved AUCs of 0.905, 0.795, and 0.818 for predicting recurrence, pCR, and dTNM, respectively, in the inner validation set from the development dataset. External validation showed that, after adjusting for clinicopathological factors, the dTNM-related radiomic signatures were independently associated with better overall survival (OS) and recurrence-free survival (RFS) (p < 0.001 and p = 0.004, respectively). Furthermore, group stratification by radiomic signatures associated with pCR and dTNM demonstrated significant differences in survival (all p < 0.001) in both external validation datasets.
[CONCLUSION] Radiomic signatures of dTNM can be a prognostic indicator for survival outcomes in breast cancer.
[CRITICAL RELEVANCE] This study demonstrates that radiomic signatures associated with dTNM offer valuable prognostic insights for survival and recurrence outcomes.
[KEY POINTS] The imaging-based model can predict longitudinal TNM staging. Radiomic signatures of dTNM demonstrate significant prognostic value. dTNM-associated radiomic signatures provide better prognostic stratification than pCR.
[MATERIALS AND METHODS] The prognostic analysis included a development cohort (n = 292) and two external validation sets (n = 180, n = 61), all with DCE-MRI data and follow-up information. A random forest-based multitask model was developed using radiomic features from DCE-MRI to predict recurrence, pathological complete response (pCR), and dTNM in the development cohort, stratifying patients into distinct groups. The model's discriminative performance was assessed with the area under the curve (AUC). In the external validation set, a multivariable Cox proportional hazards model evaluated the prognostic significance of the groups stratified by the radiomic signatures.
[RESULTS] The multitask model, incorporating 17 imaging features, achieved AUCs of 0.905, 0.795, and 0.818 for predicting recurrence, pCR, and dTNM, respectively, in the inner validation set from the development dataset. External validation showed that, after adjusting for clinicopathological factors, the dTNM-related radiomic signatures were independently associated with better overall survival (OS) and recurrence-free survival (RFS) (p < 0.001 and p = 0.004, respectively). Furthermore, group stratification by radiomic signatures associated with pCR and dTNM demonstrated significant differences in survival (all p < 0.001) in both external validation datasets.
[CONCLUSION] Radiomic signatures of dTNM can be a prognostic indicator for survival outcomes in breast cancer.
[CRITICAL RELEVANCE] This study demonstrates that radiomic signatures associated with dTNM offer valuable prognostic insights for survival and recurrence outcomes.
[KEY POINTS] The imaging-based model can predict longitudinal TNM staging. Radiomic signatures of dTNM demonstrate significant prognostic value. dTNM-associated radiomic signatures provide better prognostic stratification than pCR.
같은 제1저자의 인용 많은 논문 (5)
- Multicolor SERS-encoded immuno-cocktail for longitudinal precise tracking of CTCs phenotypes in lung cancer therapeutics.
- Role of the neurotransmitter-receptor pathway in T-cell tumor immunology and cancer immunotherapy.
- Exploratory Analysis of [ 68 Ga]Ga-FAP-2286 PET/CT Quantitative Parameters for Predicting Response to [ 177 Lu]Lu-FAP-2286 Therapy in Non-small Cell Lung Cancer.
- Deep learning synthesis of DBT features from mammography for breast cancer diagnosis.
- Joint synthesis of longitudinal MRI and enhanced prediction of neoadjuvant chemotherapy response in breast cancer: a multicohort study.